Literature DB >> 32365353

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform.

Tran Thi Nhu Thao1,2,3, Fabien Labroussaa2,4, Nadine Ebert1,2, Philip V'kovski1,2, Hanspeter Stalder1,2, Jasmine Portmann1,2, Jenna Kelly1,2, Silvio Steiner1,2,3, Melle Holwerda1,2,3,5, Annika Kratzel1,2,3, Mitra Gultom1,2,3,5, Kimberly Schmied1,2, Laura Laloli1,2,3,5, Linda Hüsser1,2, Manon Wider5, Stephanie Pfaender1,2,6, Dagny Hirt1,2, Valentina Cippà2,4, Silvia Crespo-Pomar2,4, Simon Schröder7, Doreen Muth7,8, Daniela Niemeyer7,8, Victor M Corman7,8, Marcel A Müller7,8,9, Christian Drosten7,8, Ronald Dijkman1,2,5, Joerg Jores10,11, Volker Thiel12,13.   

Abstract

Reverse genetics has been an indispensable tool to gain insights into viral pathogenesis and vaccine development. The genomes of large RNA viruses, such as those from coronaviruses, are cumbersome to clone and manipulate in Escherichia coli owing to the size and occasional instability of the genome1-3. Therefore, an alternative rapid and robust reverse-genetics platform for RNA viruses would benefit the research community. Here we show the full functionality of a yeast-based synthetic genomics platform to genetically reconstruct diverse RNA viruses, including members of the Coronaviridae, Flaviviridae and Pneumoviridae families. Viral subgenomic fragments were generated using viral isolates, cloned viral DNA, clinical samples or synthetic DNA, and these fragments were then reassembled in one step in Saccharomyces cerevisiae using transformation-associated recombination cloning to maintain the genome as a yeast artificial chromosome. T7 RNA polymerase was then used to generate infectious RNA to rescue viable virus. Using this platform, we were able to engineer and generate chemically synthesized clones of the virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4, which has caused the recent pandemic of coronavirus disease (COVID-19), in only a week after receipt of the synthetic DNA fragments. The technical advance that we describe here facilitates rapid responses to emerging viruses as it enables the real-time generation and functional characterization of evolving RNA virus variants during an outbreak.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32365353     DOI: 10.1038/s41586-020-2294-9

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  129 in total

1.  A platform for RNA virus cloning.

Authors:  Linda Koch
Journal:  Nat Rev Genet       Date:  2020-07       Impact factor: 53.242

Review 2.  A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.

Authors:  Priyanka Dash; Subhashree Mohapatra; Sayantan Ghosh; Bismita Nayak
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

3.  Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants.

Authors:  Wendy K Jo; Alina Schadenhofer; Andre Habierski; Franziska K Kaiser; Giulietta Saletti; Tina Ganzenmueller; Elias Hage; Sibylle Haid; Thomas Pietschmann; Gesine Hansen; Thomas F Schulz; Guus F Rimmelzwaan; Albert D M E Osterhaus; Martin Ludlow
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

4.  A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery.

Authors:  Yun-Yun Jin; Hanwen Lin; Liu Cao; Wei-Chen Wu; Yanxi Ji; Liubing Du; Yiling Jiang; Yanchun Xie; Kuijie Tong; Fan Xing; Fuxiang Zheng; Mang Shi; Ji-An Pan; Xiaoxue Peng; Deyin Guo
Journal:  Virol Sin       Date:  2021-05-17       Impact factor: 4.327

5.  A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses.

Authors:  Alberto A Amarilla; Julian D J Sng; Rhys Parry; Joshua M Deerain; James R Potter; Yin Xiang Setoh; Daniel J Rawle; Thuy T Le; Naphak Modhiran; Xiaohui Wang; Nias Y G Peng; Francisco J Torres; Alyssa Pyke; Jessica J Harrison; Morgan E Freney; Benjamin Liang; Christopher L D McMillan; Stacey T M Cheung; Darwin J Da Costa Guevara; Joshua M Hardy; Mark Bettington; David A Muller; Fasséli Coulibaly; Frederick Moore; Roy A Hall; Paul R Young; Jason M Mackenzie; Jody Hobson-Peters; Andreas Suhrbier; Daniel Watterson; Alexander A Khromykh
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919

6.  Generation of restriction endonucleases barcode map to trace SARS-CoV-2 origin and evolution.

Authors:  Federico Colombo; Elisa Corsiero; Myles J Lewis; Costantino Pitzalis
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

7.  Dual-Fluorescence Labeling Pseudovirus for Real-Time Imaging of Single SARS-CoV-2 Entry in Respiratory Epithelial Cells.

Authors:  Yingxin Ma; Guobin Mao; Guoqiang Wu; Minghai Chen; Fujun Qin; Luping Zheng; Xian-En Zhang
Journal:  ACS Appl Mater Interfaces       Date:  2021-05-07       Impact factor: 9.229

8.  Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation.

Authors:  Musa Khaitov; Alexandra Nikonova; Igor Shilovskiy; Ksenia Kozhikhova; Ilya Kofiadi; Lyudmila Vishnyakova; Alexander Nikolskii; Pia Gattinger; Valeria Kovchina; Ekaterina Barvinskaia; Kirill Yumashev; Valeriy Smirnov; Artem Maerle; Ivan Kozlov; Artem Shatilov; Anastasiia Timofeeva; Sergey Andreev; Olesya Koloskova; Nadezhda Kuznetsova; Daria Vasina; Maria Nikiforova; Sergei Rybalkin; Ilya Sergeev; Dmitriy Trofimov; Alexander Martynov; Igor Berzin; Vladimir Gushchin; Aleksey Kovalchuk; Sergei Borisevich; Rudolf Valenta; Rakhim Khaitov; Veronica Skvortsova
Journal:  Allergy       Date:  2021-05-10       Impact factor: 14.710

Review 9.  Applications of Deep Mutational Scanning in Virology.

Authors:  Thomas D Burton; Nicholas S Eyre
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

Review 10.  SARS-CoV-2 one year on: evidence for ongoing viral adaptation.

Authors:  Thomas P Peacock; Rebekah Penrice-Randal; Julian A Hiscox; Wendy S Barclay
Journal:  J Gen Virol       Date:  2021-04       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.